A method of forming an aqueous dispersion, the method comprising mixing: (i) an organic phase comprising a lipid mixture comprising a cationic or cationically ionisable lipid dissolved in a water-soluble organic solvent; and (ii) an aqueous phase, the aqueous phase comprising an aqueous amino acid, or a mixture thereof; to produce the aqueous dispersion, is disclosed. Aqueous dispersions prepared by the method, nucleic acid-lipid particles and methods of preparing them using the aqueous dispersion, and their use in medicine, are also disclosed.
A61K 9/1272 - Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
A61K 47/22 - Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
An aqueous dispersion having an aqueous mobile phase and a dispersed phase, wherein: the dispersed phase comprises a lipid mixture including a cationically ionizable lipid; and the aqueous mobile phase comprises a buffer solution having a pH from about 6.5 to about 8; wherein the aqueous dispersion is substantially free of inorganic cations, organic solvents and nucleic acids, is described. Methods of preparing the aqueous dispersion, nucleic acid-lipid particles and methods of preparing them using the aqueous dispersion, and their use in medicine are disclosed.
A61K 9/1272 - Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
A61K 47/22 - Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
The present disclosure provides T cell receptors (TCRs) against peptide-MHC complexes, isolated nucleic acid molecules encoding TCRs against peptide-MHC complexes, T cells expressing TCRs against peptide-MHC complexes, and pharmaceutical compositions for use in the treatment of diseases.
123455, L, Y, BM and q have the meanings defined herein, are provided. Processes for preparing the compounds and their used in a variety of medical applications, in particular in the treatment of cancer, are also provided.
6711, U, D, BM, and q have the meanings defined herein, are provided. Processes for preparing the compounds and their uses in a variety of medical applications, in particular in the treatment of cancer, are also provided.
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
C07D 491/22 - Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups , , or in which the condensed system contains four or more hetero rings
The invention relates to agents and methods for targeted delivery of payloads to cells. The payload includes a variety of molecules such as therapeutic or diagnostic agents and, in particular, radiodiagnostics, toxins, or immunomodulators. In some embodiments, the invention involves providing to a subject a compound comprising a payload moiety and at least two tags (tag conjugate) and a compound comprising at least two binding moieties for a target antigen and a binding moiety for a tag of the tag conjugate (docking compound).
C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
7.
COMPOSITIONS FOR DELIVERY OF PLASMODIUM RH5 ANTIGENS AND RELATED METHODS
The present disclosure provides compositions (e.g., pharmaceutical compositions) for delivery of malarial protein antigens and related technologies (e.g., components thereof and/or methods relating thereto). Among other things, the present disclosure provides polyribonucleotides encoding malarial protein antigens.
A composition comprising: (a) an active ingredient; and (b) a lipid mixture comprising: (i) a cationically ionisable lipid capable of forming a lipid nanoparticle; (ii) a steroid; and (iii) a negatively charged amphiphile having a hydrophilic portion and a lipophilic portion; wherein the composition is a lipid nanoparticle composition and is substantially free of a polyethylene glycol-conjugated lipid, wherein the polyethylene glycol (PEG) moiety of the PEG-conjugated lipid has at least 5 consecutive ethylene glycol repeating units, is provided.
A61K 9/1272 - Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
A61K 31/711 - Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
A61K 39/00 - Medicinal preparations containing antigens or antibodies
C12N 15/88 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using liposome vesicle
The present disclosure provides compositions (e.g., pharmaceutical compositions) for delivery of anti-HIV antibody agents and related technologies (e.g., components thereof and/or methods relating thereto). Among other things, the present disclosure provides polyribonucleotides encoding an immnunoglobulin chain of an anti-HIV antibody agent.
Presented herein are methods and systems that allow biophysical and/or genomic properties of tumor samples to be determined via analysis of sequencing data, obtained, for example, via next-generation sequencing of tumor samples from a subject. Among other things, tumor deconvolution technologies of the present disclosure identify and analyze mutations, such as single nucleotide variations (SNVs) that occur in cancer cells, to characterize tumor samples, for example by estimating tumor sample purity. Among other things, obtaining accurate estimates of tumor sample purity allows putative mutations to be detected and/or confirmed as actual, underlying physical, somatic mutations present in cancer cells at high levels of accuracy. In turn, an accurate list of somatic mutations characteristic of a subject's cancer can be used to diagnose the patient, determine treatment - for example via selection of targeted therapies, and/or develop personalized treatments, such as individualized cancer vaccines.
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
G16B 20/20 - Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
11.
TECHNOLOGIES FOR DETERMINING TUMOR SAMPLE PURITY AND/OR GENOMIC CHARACTERISTICS
Presented herein are methods and systems that allow biophysical and/or genomic properties of tumor samples to be determined via analysis of sequencing data, obtained, for example, via next-generation sequencing of tumor samples obtained from a subject. Among other things, tumor deconvolution technologies of the present disclosure leverage signals in sequencing data that originate from copy number variation (CNV) events that occur in cancer cells to estimate tumor sample purity and/or determine genomic properties, such as absolute copy numbers of segments within a tumor genome. Among other things, accurate assessments of tumor sample purity and/or genomic properties made possible via techniques described herein can be utilized to accurately detect and characterize cancer-specific mutations, such as single nucleotide variations (SNVs) that may serve as targets for personalized cancer therapies.
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
G16B 20/20 - Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
12.
TECHNOLOGIES FOR MUTATION DETECTION USING TUMOR MODELING AND FEEDBACK
Presented herein are methods and systems that allow for identification and selection of tumor cell mutations that represent/correspond to high quality neoantigen epitope targets for cancer immunotherapy, such as for inclusion in personalized cancer vaccines (PCVs), use in T- cell therapies, T-cell receptor (TCR)-based therapies, etc.
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
G16B 20/20 - Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
13.
TECHNOLOGIES FOR NEOANTIGEN PRIORITIZATION BASED ON TUMOR MODELING AND CLONALITY STATES
Presented herein are methods and systems that allow for identification and selection of tumor cell mutations that represent/correspond to high quality neoantigen epitope targets for cancer immunotherapy, such as for inclusion in personalized cancer vaccines (PC Vs), use in T-cell therapies, T-cell receptor (TCR)-based therapies, etc.
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
The present invention relates to combination therapy using an RNA anti-cancer vaccine in combination with a binding agent that binds to (i) PD-1, PD-L1, or both, and (ii) VEGF, VEGF receptor (VEGFR), or both to reduce or prevent progression of cancer or to treat cancer.
C07K 16/22 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
This disclosure relates to the field of RNA to prevent or treat multiple infectious agents. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection and influenza virus infection and inducing effective coronavirus and influenza virus antigen-specific immune responses such as antibody and/or T cell responses.
The present invention provides a binding agent that binds to EpCAM and to CD137 which is useful to treat or prevent a tumor or cancer, or to prevent progression of a tumor or cancer.
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A method of quantifying RNA capping efficiency, the method comprising: (a) providing a sample of capped RNA; (b) contacting the capped RNA with a nuclease, wherein the nuclease is a protein, thereby hydrolysing the RNA to produce hydrolysis products comprising a capped product comprising dinucleotides, and an uncapped product comprising nucleotides, step (b) being carried out in the absence of a nucleic acid having a base sequence complementary to the sequence of the capped RNA; (c) separating the hydrolysis products by chromatography; and (d) determining the concentrations of the hydrolysis products by triple quadrupole mass spectrometry, thereby quantifying RNA capping efficiency; is provided.
The present invention relates to an anti-CTLA4 antibody or fragment thereof for use in a method of treating non-small cell lung cancer in a subject in need thereof, wherein the non-small cell lung cancer has a squamous histology. The invention further provides a method of treating non-small cell lung cancer in a subject in need thereof, wherein the method comprises administering the anti-CTLA4 antibody or fragment thereof to the subject, and wherein the non-small cell lung cancer has a squamous histology. The invention also provides a composition comprising the anti-CTLA4 antibody or fragment thereof for use in a method of treating non-small cell lung cancer in a subject in need thereof, wherein the non-small cell lung cancer has a squamous histology.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The present invention relates to a method of measuring nucleic acid integrity in a composition of lipid nanoparticles (LNPs) comprising a cargo of nucleic acids, such as a DNA and/or RNA. In particular, the present invention relates to a method of measuring integrity of RNA in a DNA/RNA cargo of an LNP following digestion of the DNA.
The present invention relates to a method of measuring RNA integrity in a composition of lipid nanoparticles (LNPs) comprising a cargo of RNA. In particular, the present invention relates to a method of measuring RNA integrity of RNA cargo of a functionalised LNP.
The present invention relates to a combination comprising a Tumor necrosis factor (TNF) inhibitor and a Tumor necrosis factor receptor 2 (TNFR2) agonist.
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
Provided are methods and agents for treating a subject having a disease, disorder or condition characterized by a population of cells expressing two or more target antigens. The methods involve providing to the subject to be treated immune effector cells expressing a CAR compatible with adaptor-peptides, as well as administering to the subject nucleic acid molecules encoding for adaptor peptides directed at two or more target-antigens either at the same time or successively.
The present disclosure provides compositions (e.g., pharmaceutical compositions) for delivery of malarial protein antigens and related technologies (e.g., components thereof and/or methods relating thereto). Among other things, the present disclosure provides polyribonucleotides encoding malarial protein antigens.
This disclosure relates to the field of RNA to prevent or treat multiple infectious agents. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection, influenza infection, and/or RSV infection and inducing effective coronavirus, influenza virus, and/or RSV antigen-specific immune responses such as antibody and/or T cell responses. Specifically, in one embodiment, the present disclosure relates to methods comprising administering to a subject (i) a bivalent RNA vaccine encoding peptides or proteins comprising epitopes of SARS-CoV-2 spike proteins (S proteins) and (ii) a tetravalent RNA vaccine encoding peptides or proteins comprising epitopes of hemagglutinin (HA), for inducing an immune response against coronavirus S proteins, in particular S proteins of SARS-CoV-2, and influenza proteins, in particular HA proteins of type A and type B influenza viruses, in the subject.
Presented herein are technologies for identifying non-canonical polypeptide targets within a sample via mass-spectrometry. Among other things, non-canonical target detection technologies leverage machine-learning classifiers along with unique input feature design to eliminate and/or mitigate false positive identifications that can plague attempts to detect small quantities of non-canonical polypeptide targets in biological samples. Accordingly, methods and systems of the present disclosure address significant shortcomings of previous mass-spectrometry data analysis techniques that rendered them unsuitable for detecting targets from the "dark" proteome. In doing so, technologies of the present disclosure facilitate target identification for immunotherapies, including treatments for cancer and/or infectious diseases.
Disclosed herein are RNA polynucleotides comprising a 5′ Cap, a 5′ UTR comprising a cap proximal sequence disclosed herein, and a sequence encoding a payload. Also disclosed herein are compositions and medical preparations comprising the same, and compositions and methods of making and using the same.
C07H 21/02 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
The present disclosure provides agents and methods for preventing or treating tuberculosis using RNA. The RNA encoding variants of antigens of Mycobacterium tuberculosis ox of fragments thereof is formulated and administered in a way that the variants are produced by cells of a subject, in particular after intramuscular or intravenous administration of the RNA.
The present disclosure provides complexes and methods of use. In some embodiments, a complex described herein is a complex comprising a cationic polymer, an anionic polymer, and a monomeric RNA molecule, wherein the cationic polymer and the monomeric RNA molecule form a core complex encapsulated by the anionic polymer. In some embodiments, a complex comprises a linear cationic polymer, an anionic polymer, and a monomeric RNA molecule, wherein the cationic polymer and the monomeric RNA molecule form a core complex encapsulated by the anionic polymer.
A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
A61K 47/22 - Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
B82Y 5/00 - Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
C12N 15/67 - General methods for enhancing the expression
C12N 15/88 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using liposome vesicle
The present disclosure is directed to a cartridge for storage of at least one reagent for a reaction in a pharmaceutical process, the cartridge comprising a housing, a cartridge inlet for fluid connection to a fluid supply, in particular a pressurized air supply, a cartridge outlet for fluid connection to and discharge via a reaction vessel, at least one reservoir for storing the reagent, and at least one channel, directly or indirectly and in at least one operational state of the cartridge, fluidly connecting the cartridge inlet, the at least one reservoir and the cartridge outlet.
The present invention is concerned with antibodies or fragments thereof as well as fusion proteins comprising the same, and nucleic acids encoding the afore-mentioned antibodies or fragments thereof or fusion proteins, wherein a constant heavy chain 1 (CH1) domain and a constant light chain (CL) domain of the antibody, fragment or fusion protein comprise specific amino acid substitutions as disclosed herein. The specific amino acid substitutions result in a preferential pairing of the CH1 and CL domains with the specific amino acid substitutions such that mispairing with one or more constant heavy chain 1 (CH1) domain and a constant light chain (CL) domain of a different amino acid sequence can be strongly reduced, if not avoided. The present invention is in particular relevant for at least one nucleic acid encoding a multispecific antibody or fragment thereof or fusion protein or a mixture of antibodies or fragments thereof or fusion proteins, wherein the at least one nucleic acid may be administered to a patient to have the encoded antibody or fragment thereof or fusion protein produced by the patient's cells. The present invention is also concerned with in vitro methods of determining correct pairing between heavy and light chains.
The present invention relates to modulators of TNF signalling for use in treating and/or preventing acute pain. In particular, a modulator of TNF signalling may be a tumour necrosis factor receptor 2 (TNFR2) agonist comprising (i) a TNFR2 binding domain comprising three TNF homology domains (THD) that specifically bind to TNFR2; and (ii) an Fc domain. The present invention further relates to combinations of a TNFR2 agonist and an inhibitor of tumour necrosis factor receptor 1 (TNFR1) signalling.
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
A method of producing a composition containing a nucleic acid-lipid particle, the method comprising the steps (a) to (d): (a) preparing a first mixture which is a lipid mixture comprising a cationically ionizable lipid in a water-soluble organic solvent; (b) preparing a second mixture in aqueous solution, the second mixture comprising (i) a nucleic acid and (ii) malate buffer; (c) mixing the first mixture with the second mixture to produce an intermediate composition comprising the nucleic acid-lipid particle; and (d) further processing of the intermediate composition by buffer exchange, wherein the buffer used in the buffer exchange comprises tris(hydroxymethyl)-aminomethane (Tris) and/or a pharmaceutically acceptable salt thereof, to produce the composition comprising the nucleic acid-lipid particle; is provided.
A61K 9/1271 - Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
A61K 9/1272 - Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 9/19 - Particulate form, e.g. powders lyophilised
The present invention relates to binding agents binding to receptors of the TNF superfamily, in particular binding agents binding to at least two different receptors of the TNF superfamily, as well as to their use in medicine. The present invention further relates to nucleic acid molecules encoding such binding agents, to cells comprising such nucleic acid molecules and to pharmaceutical compositions and kits.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
35.
PEPTIDOGLYCAN HYDROLASES HAVING A CHAP DOMAIN WITH ENGINEERED ACTIVE SITE
The present invention is generally in the fields of pharmaceuticals, in particular antibacterials, and protein engineering. In particular, the present invention relates to peptidoglycan hydrolases such as endolysins and nucleic acids, e.g., RNAs, encoding the peptidoglycan hydrolases of the invention, as well as medical uses thereof, for example, for treating diseases caused by and/or associated with a Staphylococcus (e.g., S. aureus) infection.
C07K 14/31 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
C12N 9/80 - Hydrolases (3.) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in linear amides
The present invention is generally in the fields of pharmaceuticals, in particular antibacterials, and protein engineering. In particular, the present invention relates to peptidoglycan hydrolases such as endolysins and nucleic acids, e.g., RNAs, encoding the peptidoglycan hydrolases of the invention, as well as medical uses thereof, for example, for treating diseases caused by and/or associated with a Staphylococcus (e.g., S. aureus) infection.
C07K 14/31 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
C12N 9/80 - Hydrolases (3.) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in linear amides
The present disclosure provides T cell receptors (TCRs) against peptide-MHC complexes, isolated nucleic acid molecules encoding TCRs against peptide-MHC complexes, T cells expressing TCRs against peptide-MHC complexes, and pharmaceutical compositions for use in the treatment of HPV associated disease or cancer.
The present invention relates to methods for treating platinum-resistant ovarian cancer in a subject using a combination of an anti-CTLA4 antibody and an anti-PD-1 antibody.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The present invention relates to methods for providing single-stranded RNA (ssRNA). Furthermore, the present invention relates to the ssRNA which is obtainable by the methods of the invention and the use of such ssRNA in therapy.
The present invention relates to minimal polypeptide-encoding RNA molecules, in particular, RNA molecules that lack or comprise shortened regulatory sequences as compared to those found in eukaryotic mRNAs, which are thus more amenable to chemical synthesis. The invention also encompasses compositions comprising distinct populations of said RNA molecules, each encoding a unique polypeptide, and methods for manufacturing and using the RNA molecules or compositions.
The present disclosure provides methods for identifying T-cell receptors (TCRs) from sequencing data, and TCR sequences identified using the methods. The methods can comprise identifying a TCR alpha chain, a TCR beta chain, a TCR gamma chain, or a TCR delta chain from the sequencing data, and then identifying the corresponding paired chain. The "de novo" method can comprise the identification of statistically associated TCR chain sequences by assessing patients' antigenic status and/or HLA alleles. In the "bait" method, a TCR chain sequence of a TCR known to have some degree of antigen reactivity can be used to search for related sequences in the large database. Resulting sequences may or may not exhibit statistical enrichments that can be detected using the "de novo" approach. Various pairing methods are provided. Identified paired TCR chains can be used for preparing various therapies including cell-based therapies.
A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
A61K 31/711 - Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
C07K 16/08 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/32 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products from oncogenes
C07K 16/40 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against enzymes
C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
C12N 15/62 - DNA sequences coding for fusion proteins
A61K 39/00 - Medicinal preparations containing antigens or antibodies
The invention provides potency assays for simultaneously analyzing at least two different nucleic acid sequences such as RNA and/or DNA sequences encoding a functional sequence such as an antigen or epitope. The potency assays of the present invention may be performed with nucleic acid sequences encoding at least two different functional sequences, including at least two different antigens or epitopes.
Disclosed herein are compositions comprising protein antigens and RNA encoding the same (eg., compositions comprising protein antigens and RNA encoding antigens) that can be used to induce an immune response against SARS-CoV-2. Also disclosed herein are immunogenic compositions and medical preparations comprising the same, and methods of making and using the same. In some embodiments, the technologies provided herein can be used to address and/or overcome immune imprinting in SARS-CoV-2.
The disclosure provides agents and methods for preventing or treating diseases associated with one or more antigens. The agents of the invention comprise RNA encoding chimeric proteins comprising an antigenic region. The antigenic region comprises one or more disease-associated antigens, immunogenic variants of fragments thereof. According to the invention, the chimeric proteins, in addition to the antigenic region, comprise a transmembrane domain and cytoplasmatic region, one or both of which are derived from a MHC-I homolog non-native to an organism from which the antigen originates.
1 BNT ref [P1819WO01] // C&F ref. 240673WO A b s t r a c t The present invention relates to an anti-CTLA4 antibody or fragment thereof and/or a chemotherapy agent for use in a method of treating cancer in a subject in need thereof, wherein the subject is administered a combination comprising the anti-CTLA4 antibody or fragment thereof and the chemotherapy agent. The invention further provides a composition 5 and a kit of parts comprising the anti-CTLA4 antibody or fragment thereof and the chemotherapy agent. The invention further concerns a method of treating cancer in a subject in need thereof, wherein the method comprises administering to the subject the anti-CTLA4 antibody or fragment thereof and the chemotherapy agent. The invention further provides a combination of the anti-CTLA4 antibody or fragment thereof and the chemotherapy agent. 10
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 31/337 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
The disclosure provides agents and methods for preventing or treating tuberculosis using RNA. The RNA encoding antigens of Mycobacterium tuberculosis, immunogenic variants or fragments thereof is formulated and administered in a way that the antigens, variants or fragments are produced by cells of a subject, in particular after intramuscular or intravenous administration of the RNA.
TRON-Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz (Germany)
Inventor
Sahin, Ugur
Paret, Claudia
Vormbrock, Kirsten
Bender, Christian
Simon, Petra
Hartmann, Christoph
Hubich, Stefanie
Bukur, Thomas
Litzenberger, Thorsten
Abstract
The present invention relates to the treatment of cancer, in particular breast cancer, particularly triple-negative breast cancer. More particularly, the invention concerns methods and means for cancer treatment involving a specific set of tumor antigens.
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
A61K 39/00 - Medicinal preparations containing antigens or antibodies
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
The present disclosure provides methods and systems for preparing a pharmaceutical composition comprising a plurality of nucleic acid particles, the method comprising contacting a nucleic acid solution with an organic solution via a mixer configured to receive the nucleic acid solution and the organic solution, wherein: the organic solution comprises an organic solvent and an oligosaccharide comprising one or more cationic moieties.
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
C12N 15/88 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using liposome vesicle
The invention relates to agents and methods for targeted delivery of payloads to cells. The payload comprises immunomodulators as further specified herein. In some embodiments, the invention involves providing to a subject a compound comprising a payload moiety and at least one tag (e.g., at least two tags) (tag conjugate) and a compound binding to the tag(s) of the tag conjugate and a target antigen, e.g., a cell surface antigen on a target cell, (docking compound).
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
A61K 47/66 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
A method of producing a nucleic acid-lipid particle, the method comprising: (a) preparing an aqueous dispersion of an intermediate lipid particle using a lipid mixture including a cationic or cationically ionizable lipid, and a cryoprotectant; (b) lyophilising the aqueous dispersion of the intermediate lipid particle; and (c) reconstituting the lyophilised intermediate lipid particle with a solution containing a nucleic acid, to produce the nucleic acid-lipid particle, is provided.
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 9/1272 - Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
A61K 9/1278 - Post-loading, e.g. by ion or pH gradient
A61K 9/19 - Particulate form, e.g. powders lyophilised
A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
The present invention generally relates to nucleic acid particles, in particular nucleic acid-lipid particles, comprising targeting moieties that are bound to the particles, and to pharmaceutical compositions containing the nucleic acid particles and their uses in medicine.
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
C12N 15/88 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using liposome vesicle
A61K 39/00 - Medicinal preparations containing antigens or antibodies
54.
RNA LIPID NANOPARTICLES (LNPs) COMPRISING A POLYOXAZOLINE AND/OR POLYOXAZINE POLYMER
The present disclosure relates to RNA nanoparticles (LNPs) for delivery of RNA to target tissues after administration, in particular after parenteral administration such as intravenous, intramuscular, subcutaneous, intratumoral, intraarterial, intradermal, dermal, intranasal, rectal or oral administration, and compositions comprising such RNA LNPs. The RNA LNPs in some embodiments comprise single-stranded RNA such as mRNA which encodes a peptide or protein of interest, such as a pharmaceutically active peptide or protein. The RNA is taken up by cells of a target tissue and the RNA is translated into the encoded peptide or protein, which may exhibit its physiological activity. Furthermore, the present disclosure relates to certain conjugates of (a) a polyoxazoline (POX) and/or polyoxazine (POZ) polymer and (b) one or more hydrophobic chains, compositions comprising such conjugates, and the uses of such conjugates and compositions.
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
C12N 15/88 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using liposome vesicle
The present disclosure provides compositions (e.g., pharmaceutical compositions) for delivery of anti-HIV antibody agents and related technologies (e.g., components thereof and/or methods relating thereto). Among other things, the present disclosure provides polyribonucleotides encoding an immunoglobulin chain of an anti-HIV antibody agent.
The present disclosure provides computational methods for designing superior T cell epitopes followed by experimental verification, feedback and further improvement of cleavage linkers between certain epitopes.
The present invention relates to a polynucleotide encoding a polypeptide, wherein the polypeptide comprises at least 25 fragments of at least two EBV proteins, each fragment having a length of at most 15 amino acids, and one or more cleavage-enhancing linker, each located between two fragments.
THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (USA)
Inventor
Furtado, Raquel Mariska
Walls, Alexandra
Palowitch, Gavin
Dulberger, Charles Lefco
Friedman, Harvey
Cohen, Gary H.
Cairns, Tina M.
Hook, Lauren Michelle
Abstract
The present disclosure provides compositions for delivery of HSV antigens and related technologies (e.g., components thereof and/or methods relating thereto).
The present invention provides humanized versions of single-domain antibodies specifically binding the epitope tag of SRLEEELRRRLTE (SEQ ID NO: 2), which can be used for binding, detection, immobilization, isolation or purification a protein comprising the said epitope tag. Furthermore, the present invention relates to a nucleic acid encoding the humanized antibody and a vector comprising the nucleic acid, as well as a host cell comprising the nucleic acid or the vector described herein.
The present invention relates to a method for producing large quantities of double stranded DNA material in an amount suitable for downstream applications, such as for in vitro transcription of RNA for therapeutic use. In particular, the present invention relates to a method of performing polymerase chain reaction (PCR) using a microwave synthesis reactor.
The present disclosure relates generally to nucleic acid-lipid particles, in particular functionalized nucleic acid-lipid particles, methods for producing them, to aqueous dispersions suitable for forming the nucleic acid-lipid particles and methods for producing them, and to pharmaceutical compositions containing them and their uses in medicine.
A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
A61P 31/00 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
C12N 15/88 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using liposome vesicle
A61K 39/00 - Medicinal preparations containing antigens or antibodies
62.
COMBINATION THERAPY WITH AN ANTI-CA19-9 ANTIBODY AND FOLFIRINOX IN THE TREATMENT OF CANCER
The present invention provides a combination therapy for effectively treating and/or preventing diseases associated with cells expressing CA19-9, including cancer diseases such as pancreatic cancer and metastases thereof.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 31/4745 - QuinolinesIsoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenanthrolines
A61K 31/513 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 31/555 - Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
A61K 31/675 - Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
A61K 39/00 - Medicinal preparations containing antigens or antibodies
63.
COMPOSITIONS AND METHODS FOR TREATMENT OF MELANOMA
The invention relates to antibody drug conjugates (ADCs) comprising an antibody or fragment thereof that specifically binds to B7-H3, for use in the treatment of cancers, in particular castration-resistant prostate cancer and small-cell lung cancer. The invention also relates to compositions containing such antibody-drug conjugates, for use in the treatment of cancers.
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
The present disclosure provides, among other things, composition and uses of said compositions comprising a cationic lipid, an anionically ionizable lipid, and a nucleic acid, wherein: the cationic lipid comprises a cationic head group, a first bridge group, and a first lipid tail group; the anionically ionizable lipid comprises an anionically ionizable head group, a second bridge group, and a second lipid tail group; the cationic lipid has a lipidic volume from about 700 Å3to about 1500 Å3, and/or the anionically ionizable lipid has a lipidic volume from about 700 Å3to about 1500 Å3; or the cationic lipid and the anionically ionizable lipid have a combined lipidic volume greater than 1400 Å3. In some embodiments, the present disclosure provides new cationic lipids and new anionically ionizable lipids.
A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61P 31/00 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
C07C 15/00 - Cyclic hydrocarbons containing only six-membered aromatic rings as cyclic part
C12N 15/00 - Mutation or genetic engineeringDNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purificationUse of hosts therefor
C12N 15/88 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using liposome vesicle
C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
The present disclosure provides, among other things, composition and uses of said compositions comprising a cationic lipid, an anionically ionizable lipid, and a nucleic acid, wherein: the cationic lipid comprises a cationic head group, a first bridge group, and a first lipid tail group; the anionically ionizable lipid comprises an anionically ionizable head group, a second bridge group, and a second lipid tail group; the cationic lipid has a lipidic volume from about 700 Å3to about 1500 Å3, and/or the anionically ionizable lipid has a lipidic volume from about 700 Å3to about 1500 Å3; or the cationic lipid and the anionically ionizable lipid have a combined lipidic volume greater than 1400 Å3. In some embodiments, the present disclosure provides new cationic lipids and new anionically ionizable lipids.
A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61P 31/00 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
C07C 15/00 - Cyclic hydrocarbons containing only six-membered aromatic rings as cyclic part
C12N 15/00 - Mutation or genetic engineeringDNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purificationUse of hosts therefor
C12N 15/88 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using liposome vesicle
C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
The invention relates to antibody drug conjugates (ADCs) comprising an antibody or fragment thereof that specifically binds to B7-H3, for use in the treatment of cancers, in particular castration-resistant prostate cancer and small-cell lung cancer. The invention also relates to compositions containing such antibody-drug conjugates, for use in the treatment of cancers.
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
The present disclosure provides technologies for in vitro transcription reactions, particularly for production of pharmaceutical grade RNA, and in some embodiments for large scale production.
The present disclosure, among other things, provides technologies for predicting immune response (e.g., in response to an antigen) and for utilizing these predictions to create personalized cancer vaccines and viral vaccines. Among other things, systems, methods, and architectures describe a use of large language models (LLMs) and/or multi-task models for immune response predictions. The present disclosure provides models that simultaneously predict multiple immune response tasks and/or benefit from training on multiple immune response tasks. The present disclosure also provides tools for identifying antigen fragments that will, among other things, be presented as ligands for T-cell recognition.
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
The invention relates to a combination of a bispecific antibody that comprises an antibody or fragment thereof that specifically binds to PD-L1 and an antibody or fragment thereof that specifically binds to VEGF, and an antibody-drug conjugate comprising an antibody or fragment thereof that specifically binds to a target expressed on the surface of a tumour cell.
C07K 16/22 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
The invention relates to a combination of a binding agent comprising (i) a first binding region which binds to PD-1, PD-L1, or both and which antagonizes the PD-1/PD-L1 interaction; and (ii) a second binding region which binds to VEGF, VEGF receptor (VEGFR), or both and which antagonizes the VEGF/VEGFR interaction, and an antibody-drug conjugate comprising an antibody or fragment thereof that specifically binds to a target expressed on the surface of a tumour cell.
C07K 16/22 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
The invention relates to binding molecule-payload conjugates (BPCs) comprising a binding molecule and one or more payload moieties, wherein the binding molecule specifically binds to CA19-9, such as for use in the treatment of pancreatic ductal adenocarcinoma (PDAC).
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
The present disclosure provides nucleic acid particles comprising an immunomodulator, RNA, and a cationic lipid or a cationic polymer, wherein nucleic acid particles described herein reduce inflammatory response and/or increase protein or antigen expression associated with previous formulations.
The present disclosure relates to RNA particles for delivery of RNA to target tissues after administration, in particular after parenteral administration such as intravenous, intramuscular, subcutaneous or intratumoral administration, and compositions comprising such RNA particles. The RNA particles in one embodiment comprise single-stranded RNA such as mRNA which encodes a peptide or protein of interest, such as a pharmaceutically active peptide or protein. The RNA is taken up by cells of a target tissue and the RNA is translated into the encoded peptide or protein, which may exhibit its physiological activity.
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
A61K 9/127 - Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
A61K 47/28 - Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
C12N 15/88 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using liposome vesicle
75.
METHODS OF TREATING PANCREATIC CANCER WITH A PD-1 AXIS BINDING ANTAGONIST AND AN RNA VACCINE
The present disclosure provides methods for treating an individual with pancreatic cancer with an individualized cancer vaccine and a PD-1 axis antagonist.
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 9/1272 - Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
C07K 14/74 - Major histocompatibility complex [MHC]
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
76.
USE OF ANTI-HER3 ANTIBODY-DRUG CONJUGATES IN CANCER TREATMENT
The invention provides an antibody-drug conjugate comprising an anti-HER3 antibody or fragment thereof linked to a TOPO1 inhibitor drug via a linker unit, for use in treating a cancer selected from the group consisting of brain tumour, lung cancer, bladder cancer, stomach cancer, ovarian cancer, peritoneal cancer, pancreatic cancer, breast cancer, head and neck cancer, cervical cancer, endometrial cancer, liver cancer, kidney cancer, urothelial cancer, epidermal cancer, non-Hodgkin lymphoma, central nervous system tumour, or thyroid cancer; wherein the use comprises administering the antibody-drug conjugate or pharmaceutically acceptable salt thereof to a patient at a dose in the ranges as defined herein. Specific antibody-drug conjugates for use in treating breast cancer are also provided.
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
The present disclosure relates to a method of treating non-small cell lung cancer in human subjects using a combination therapy of a bispecific antibody binding to PD-L1 and to CD 137 and a PD-1 antagonist.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
A61K 39/00 - Medicinal preparations containing antigens or antibodies
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
80.
PHARMACEUTICAL COMPOSITIONS FOR DELIVERY OF HERPES SIMPLEX VIRUS ANTIGENS AND RELATED METHODS
The Trustees of the University of Pennsylvania (USA)
Inventor
Sahin, Ugur
Rooney, Michael Steven
Esaulova, Ekaterina
Zuiani, Adam
Addona, Theresa
Poran, Asaf
Goulding, Scott
Sanchez Velazquez, Ricardo
Uebele, Julia
Güler, Alptekin
Cohen, Gary H.
Friedman, Harvey
Awasthi, Sita
Abstract
The present disclosure provides pharmaceutical compositions for delivery of HSV antigens (e.g., an HSV vaccine) and related technologies (e.g., components thereof and/or methods relating thereto).
A61K 39/245 - Herpetoviridae, e.g. herpes simplex virus
A61K 9/1272 - Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
The present disclosure relates generally to nucleic acid-lipid particles, in particular functionalised nucleic acid-lipid particles, methods for producing them, and to pharmaceutical compositions containing them and their uses in medicine.
A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
C12N 15/88 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using liposome vesicle
82.
METHODS FOR IDENTIFYING EXHAUSTED T CELLS AND T-CELL RECEPTORS THEREOF
The present disclosure provides methods and compositions to identify exhausted T cells from a population of T cells extracted from a tumor microenvironment in cancer patients. The present disclosure also provides methods and compositions to identify tumor-reactive T-cell receptor (TCR) clonotypes. The present disclosure also provides methods and compositions to identify tumor-reactive TCR clonotypes from the exhausted T cells identified using the methods described herein. The present disclosure utilizes advanced prediction algorithms and next-generation sequencing technologies, like single-cell transcriptome (scGEX) and TCR sequencing (scTCR), to identify TCR clonotypes within a tumor. The methods can distinguish each T cell as either a CD4+ or CD8+ cell based on the expression level of classification genes. The classification can create distinct CD4+ and CD8+ clusters. A CD4+ exhaustion score and/or a CD4+ gene set enrichment analysis (GSEA) score can be calculated for T cells in the CD4+ cluster, and similarly, a CD8+ exhaustion score and/or a CD8+ GSEA score for T cells in the CD8+ cluster. These scores can be calculated based on the expression level of specific exhaustion gene markers. Any T cell exceeding a set of exhaustion score and/or GSEA score threshold can be identified as exhausted. TCR clonotypes can be identified and ranked in the exhausted T cells for further applications.
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
G16B 25/10 - Gene or protein expression profilingExpression-ratio estimation or normalisation
The present disclosure, among other things, provides machine-learning technologies for identifying and localizing particular genomic elements (e.g., gene elements and/or regulatory elements) within nucleotide sequences, such as DNA and/or RNA sequences. In certain embodiments, similar to the manner in which image processing methods can be used to localize particular objects in images at pixel level resolution, referred to as “segmentation,” systems and methods of the present disclosure predict presence and locations of certain genomic elements within nucleotide sequences, thereby “segmenting” nucleotide sequences. Accordingly, genomic element segmentation technologies described herein may be used to generate annotations that identify and label portions of nucleotide sequences according to their predicted (e.g., via machine learning models described herein) function—e.g., as protein-coding genes, untranslated regions, splice sites, promotors, enhancers, etc. Among other things, these genomic annotations may be used to inform underlying biological processes driving diseases and facilitate development of new therapies.
The present invention relates to antibodies capable of binding to human OX40 and to variants thereof comprising a modified Fc region comprising at least one mutation that enhances the Fc-Fc interaction of the antibody and at least one mutation that reduces the Fc effector functions of the antibody. The invention further provides pharmaceutical compositions comprising the antibodies and use of the antibodies for therapeutic and diagnostic procedures, in particular in cancer therapy.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
The present disclosure provides compositions and methods for producing an engineered immune cell including a first nucleotide sequence encoding a T-cell receptor (TCR) and a second nucleotide sequence encoding a co-stimulatory receptor molecule. The present disclosure also provides methods for producing the engineered immune cells comprising a plurality of antigen specific T cells. The methods can be used to produce a therapeutically effective amount of antigen specific T cells within a short period of time. The compositions and methods provided herein can be used for the treatment of cancer.
The present invention relates to antibodies capable of binding to human OX40 and to variants thereof comprising a modified Fc region comprising at least one mutation that enhances the Fc-Fc interaction of the antibody and at least one mutation that reduces the Fc effector functions of the antibody. The invention further provides pharmaceutical compositions comprising the antibodies and use of the antibodies for therapeutic and diagnostic procedures, in particular in cancer therapy.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
The present invention relates to methods and compositions for stimulating an immune response. In particular, the present invention relates to compositions comprising an immunostimulatory RNA comprising sequences derived from an Influenza A virus nudeoprotein-encoding RNA molecule that act as adjuvants and/or immunostimulatory agents to enhance host immune responses, in particular as adjuvants for cancer vaccines.
The present invention provides combination therapy using a first binding agent comprising at least one binding region binding to CD27 in combination with a second binding agent comprising a first binding region binding to CD40 and a second binding region binding to CD137 to reduce progression or prevent progression of a tumor or treating cancer.
A61K 39/00 - Medicinal preparations containing antigens or antibodies
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The present application relates to an isolated nucleic acid comprising (i) an open reading frame encoding a protein that is not to be expressed in a specific cell but to be expressed in a cell differing from the specific cell and (ii) a miRNA target site, wherein the miRNA target site is recognized by a miRNA that is expressed in the specific cell but substantially not expressed in the cell differing from the specific cell. The present application further relates to a particle comprising the afore-mentioned isolated nucleic acid as well as a pharmaceutical composition comprising the afore-mentioned particle. The present application is also concerned with a method of expressing a protein in a cell substantially not expressing a miRNA but not expressing the protein in a cell expressing said miRNA, either in vitro or in vivo in a subject, the use of the afore-mentioned nucleic acid, particle and pharmaceutical composition to express a protein in a cell-specific manner; with a method of treating a B cell cancer, an immune cell and a kit related to the afore-mentioned aspects.
The present disclosure provides a therapy with soluble T cell receptors (TCRs) and cells comprising chimeric antigen receptors (CAR) including compositions, polynucleotides encoding the compositions and methods of use thereof. The methods and compositions provided herein can be used for the treatment of cancer.
The present disclosure provides pharmaceutical compositions for delivery of monkeypox antigens (e.g., a monkeypox vaccine) and related technologies (e.g., components thereof and/or methods relating thereto). For example, the present disclosure provides polyribonucleotides encoding one or more monkeypox antigens or fragments thereof.
The disclosure provides nucleic acid agents or compositions encoding interleukin (18) receptor polypeptides, immune effector cells transformed to overexpress interleukin (18) receptor polypeptides as well as methods of treatment involving such immune effector cells.
The present disclosure provides pharmaceutical compositions for delivery of orthopoxvirus antigens (e.g., mpox, variola, borealpox, ectromelia, cowpox, volepox, modified vaccinia virus Ankara, or vaccinia) and related technologies (e.g., components thereof and/or methods relating thereto). For example, the present disclosure provides polyribonucleotides encoding one or more mpox antigens, fragments, or fusions thereof.
The invention provides an RNA cancer vaccine and/or an anti-CTLA4 antibody for use in a method of treating cancer in a subject in need thereof, wherein the subject is administered a combination comprising the RNA cancer vaccine comprising at least one RNA and the anti- CTLA4 antibody. The invention further provides a compositions or kit of parts comprising the RNA cancer vaccine comprising the at least one RNA and the anti-CTLA4 antibody. The invention further provides methods of treating cancer in a subject in need thereof, wherein the method comprises administering to the subject the RNA cancer vaccine comprising the at least one RNA and the anti-CTLA4 antibody. The invention further provides a combination of the RNA cancer vaccine comprising at least one RNA and the anti-CTLA4 antibody. The invention further provides a combination of the RNA cancer vaccine comprising at least one RNA and the anti-CTLA4 antibody for use as a medicament.
A61K 39/00 - Medicinal preparations containing antigens or antibodies
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
The present disclosure provides compositions (e.g., pharmaceutical compositions) for delivery of shared tumor antigen epitopes and neoantigen epitopes, and related technologies (e.g., components thereof and/or methods relating thereto). Among other things, the present disclosure provides polyribonucleotides encoding polyepitopic vaccines including shared tumor antigen epitopes and polyribonucleotides encoding polyepitopic vaccines including neoantigen epitopes.
The invention provides an RNA cancer vaccine and/or an anti-CTLA4 antibody for use in a method of treating cancer in a subject in need thereof, wherein the subject is administered a combination comprising the RNA cancer vaccine comprising at least one RNA and the anti- CTLA4 antibody. The invention further provides a compositions or kit of parts comprising the RNA cancer vaccine comprising the at least one RNA and the anti-CTLA4 antibody. The invention further provides methods of treating cancer in a subject in need thereof, wherein the method comprises administering to the subject the RNA cancer vaccine comprising the at least one RNA and the anti-CTLA4 antibody. The invention further provides a combination of the RNA cancer vaccine comprising at least one RNA and the anti-CTLA4 antibody.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
01 - Chemical and biological materials for industrial, scientific and agricultural use
05 - Pharmaceutical, veterinary and sanitary products
40 - Treatment of materials; recycling, air and water treatment,
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Chemical agents for laboratory use, in particular nucleic acids, peptides and proteins; chemical agents for the production of anticancer drugs and vaccines, in particular nucleic acids, peptides and proteins. Pharmaceuticals and veterinary preparations, in particular for treating cancerous diseases, infections, autoimmune disorders and metabolic disorders; diagnostic products, namely diagnostic preparations and materials. Treatment and conversion of material, namely custom manufacturing of chemical and biochemical preparations; custom manufacturing of biopharmaceuticals, chemical agents for laboratory use, in particular nucleic acids, peptides and proteins, pharmaceutical products of all kinds, in particular for treating cancerous diseases, infections and autoimmune disorders, and of chemical agents for the production of anticancer drugs and vaccines, in particular nucleic acids, peptides and proteins; custom manufacturing of therapeutic products, namely medical and veterinary preparations. Scientific research for medical and veterinary purposes, in particular for developing treatment concepts for cancerous diseases, infections, autoimmune diseases and metabolic disorders. Medical and veterinary services in connection with the treatment of cancerous diseases, infections and autoimmune disorders and metabolic disorders.
98.
TREATMENT INVOLVING NON-IMMUNOGENIC RNA FOR ANTIGEN VACCINATION AND PD-1 AXIS BINDING ANTAGONISTS
UNIVERSITÄTSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITÄT MAINZ (Germany)
Inventor
Sahin, Ugur
Kranz, Lena Mareen
Diken, Mustafa
Hilscher, Lina
Kreiter, Sebastian
Abstract
The present disclosure relates to methods and agents for antigen vaccination and inducing effective antigen-specific immune effector cell responses such as T cell responses. These methods and agents are, in particular, useful for the treatment of diseases characterized by diseased cells expressing an antigen the immune effector cells are directed to. In some embodiments, the present disclosure relates to methods comprising administering to a subject (i) non-immunogenic RNA encoding a peptide or polypeptide comprising an epitope for inducing an immune response against an antigen in the subject, i.e., non-immunogenic RNA encoding vaccine antigen; and (ii) a PD-1 axis binding antagonist such as an anti-PD-1 antibody and/or an anti-PD-L1 antibody.
TRON-TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITÄTSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITÄT MAINZ (Germany)
Inventor
Sahin, Ugur
Weber, David
Walter, Carina
Barea Roldán, Diana
Kuner, Ruprecht
Hein, Melanie
Suchan, Martin
Kissler, Verena
Kranz, Lena Mareen
Abstract
This disclosure relates to the field of RNA to treat lung cancer, in particular non-small-cell lung carcinoma (NSCLC). Lung cancer is the third most frequent malignancy in women and the second most frequent malignancy in men. NSCLC accounts for about 85% of all lung cancers. Disclosed herein are compositions, uses, and methods for treatment of lung cancers. Administration of therapeutic RNAs to a patient having lung cancer disclosed herein can reduce tumor size, prolong time to progressive disease, and/or protect against metastasis and/or recurrence of the tumor and ultimately extend survival time.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
100.
SYSTEMS AND METHODS FOR MULTIMODAL CONVERSATIONAL AGENTS FOR BIOLOGICAL SEQUENCE ANALYSIS
Provided herein are technologies for framing and evaluating biological sequence-based analysis tasks in a unified, natural-language-based, text in and text out format. Among other things, methods and systems of the present disclosure provide machine-learning technologies for combining biological sequence data, representing, for example, DNA, RNA, and protein sequences, with natural language, conversational style prompts that set out particular analysis tasks to be performed on the biological sequence data. This approach, for example, allows complex analysis tasks, including, but not limited to, identification of various sequence modifications, genes, and regulatory elements in DNA sequences, and quantification of properties such as degradation propensity of RNA and protein stability, to be input to a machine learning model in a uniform text-based format and for output to be generated in a same, unified, text-based format.
